|
市場調查報告書
蛋白質療法的投藥技術
Delivery Technologies for Protein Therapeutics: Assessment and Outlook
|
蛋白質療法的投藥技術 是由出版商Insight Pharma Reports在2007年03月所出版的。
這份英文市場調查報告書包含185 pages 價格從美金1498起跳。
因基因領域調查工作獲得全球高度評價的美國市調公司 Insight Pharma Reports (總公司:麻薩諸塞州),針對蛋白質療法的投藥技術進行詳細的調查分析,並出版調查報告書 "Delivery Technologies for Protein Therapeutics: Assessment and Outlook" 。
本報告書內容包括:蛋白質療法的投藥技術動向、口服、經皮膚投藥技術的趨勢、蛋白質工程技術概要等。內容綱要摘記如下:
第1章 介紹:蛋白質療法的投藥技術趨勢
- 為什麼需要更好的蛋白質療法的投藥方式呢?
- 本報告書的架構
- 蛋白質工程技術
- 非注射技術
- 胰島素
- 商業及市場發展預測
- 技術趨勢什麼時候才會互相融合?
第2章 延長半衰期的治療用蛋白質工程
- 介紹
- 利用PEGylation延長半衰期
- 利用特定用途的PEGylation延長半衰期
- 利用與聚唾液酸的結合延長半衰期
- 利用清蛋白基因融合延長半衰期
- 利用與清蛋白結合延長半衰期
- 利用與清蛋白結合的脂肪酸延長半衰期
- 利用與清蛋白結合的縮氨酸延長半衰期
- 利用與連球菌清蛋白結合的範圍延長半衰期
- 利用運鐵蛋白基因的融合延長半衰期
- 利用高血糖化延長半衰期
- 利用糖甘化完成及GlycoPEGylation延長半衰期
- 利用人類化糖甘化延長半衰期
- 利用蛋白酶抗體突變延長半衰期
第3章 提昇投藥品質的其他蛋白質工程技術
- 利用生物資訊學降低免疫原性
- 利用生物資訊學使蛋白質聚集
- 利用高壓技術使蛋白質聚集摺疊
第4章 經皮膚投藥技術
- 介紹
- 利用微頻電極陣列的投藥
- 利用超音波的主動投藥
- 利用超音波的被動投藥
- 利用熱燒的投藥
- 利用離子電導入法投藥
- 利用傳遞體(Transfersomes)的投藥
第5章 口服投藥技術
- 介紹
- 利用傳遞體分子的口服投藥
- 利用結晶化技術的口服投藥
- 利用磷酸鈣奈米粒子的口服投藥
- 利用口腔噴劑的口服投藥
- 利用兩性寡合體的口服投藥
第6章 蛋白質經肺及經鼻投藥技術
- 利用乾粉吸入器對肺的投藥
- 其他蛋白質吸入技術
- 利用融合抗體轉介運輸穿胞的蛋白質對肺的投藥
- 利用黏膜吸收促進劑的經鼻投藥:第1部
- 利用黏膜吸收促進劑的經鼻投藥:第2部
- 利用緊密結合度調節的經鼻投藥
第7章 專家訪談
附錄
企業索引
參考資訊
Abstract
Some of biotech' s most celebrated successes include:
- clotting factors
- anticoagulants
- modern insulins
- growth hormone
- follicle-stimulating hormone
- hematopoietic growth factors
- interferons
- interleukins
What do they have in common? They are therapeutic proteins, a market segment
that had $34 billion in sales in 2004 and will have a projected $52.2 billion
in sales in 2010*. As patents on first-generation proteins wind down, their
owners naturally seek to protect their markets against interlopers. And in
current and future battles for market share, protein delivery technologies are
major weapons of offense and defense. It is a safe bet that if a therapeutic
protein is bringing in big money and its patent is nearing expiration, someone
somewhere with a clever technology is planning a market invasion based on
improving how the protein is delivered. Delivery Technologies for Therapeutic
Proteins: Assessment and Outlook analyzes and assesses protein delivery
technologies developed by companies that are targeting:
- improved insulin delivery
- improved erythropoietin delivery
- improved interferon delivery
- improved growth hormone delivery
The report also analyzes and assesses noninjection delivery technologies,
including technologies for:
- transdermal protein delivery
- oral protein delivery
- pulmonary protein delivery
- nasal protein delivery
Delivery Technologies for Therapeutic Proteins: Assessment and Outlook
provides a thorough analysis and assessment of technologies for protein
half-life extension and technologies for delivery of protein therapeutics.
Table of Contents
EXECUTIVE SUMMARY
Chapter 1 INTRODUCTION: TRENDS IN TECHNOLOGY FOR DELIVERING PROTEIN THERAPEUTICS
- 1.1. Why Better Delivery For Therapeutic Proteins Is Needed
- Alternatives to Injection
- 1.2. Organization of this Report
- 1.3. Protein Engineering Technologies
- 1.4. Non-Injection Technologies
- 1.5. Insulin: El Dorado of Protein Delivery Tech
- Multiple Products, Multiple Mechanisms
- 1.6. Business and Market Outlook
- Competition Among Noninjection Technologies
- 1.7. When Will Tech Trends Merge?
Chapter 2 ENGINEERING THERAPEUTIC PROTEINS FOR LONGER HALF-LIFE
- 2.1. Introduction
- 2.2. Increasing Half-life by PEGylation
- 2.3. Increasing Half-life by Site-specific PEGylation
- 2.4. Increasing Half-life by Conjugation with Polysialic Acid
- 2.5. Increasing Half-life by Albumin Gene Fusion
- 2.6. Increasing Half-life by Albumin Conjugation
- DAC and PC-DAC Technologies
- 2.7. Increasing Half-life by Albumin-binding Fatty Acids
- 2.8. Increasing Half-life by Albumin-binding Peptides
- 2.9. Increasing Half-life with the Streptococcal Albumin-binding Domain
- 2.10. Increasing Half-life by Transferrin Gene Fusion
- 2.11. Increasing Half-life by Hyperglycosylation
- 2.12. Increasing Half-life by Glycosylation Completion and GlycoPEGylation
- 2.13. Increasing Half-life by Humanized Glycosylation
- 2.14. Increasing Half-life by Protease-resistant Point Mutations
Chapter 3 OTHER PROTEIN ENGINEERING TECHNOLOGIES TO IMPROVE PROTEIN DELIVERY
- 3.1. Reducing Immunogenicity through Bioinformatics
- 3.2. Reducing Protein Aggregation through Bioinformatics
- 3.3. Refolding Protein Aggregates through High Pressure Technology
Chapter 4 TECHNOLOGIES FOR TRANSDERMAL DELIVERY OF PROTEINS
- 4.1. Introduction
- 4.2. Delivery by Radio Frequency (RF) Microelectrode Array
- 4.3. Active Delivery by Ultrasound
- U-Strip Ultrasound Module
- 4.4. Passive Delivery by Ultrasound
- 4.5. Delivery by Thermal Burst
- 4.6. Delivery by Iontophoresis
- 4.7. Delivery by Transfersomes
Chapter 5 Technologies for Oral Delivery of Proteins
- 5.1. Introduction
- 5.2. Oral Protein Delivery using Carrier Molecules
- 5.3. Oral Protein Delivery using Crystallization Technology
- 5.4. Oral Protein Delivery by Calcium Phosphate Nanoparticles
- 5.5. Oral Protein Delivery by Buccal Mouth Spray
- 5.6. Oral Protein Delivery using Amphiphilic Oligomers
Chapter 6 TECHNOLOGIES FOR PULMONARY AND NASAL DELIVERY OF PROTEINS
- 6.1. Pulmonary Delivery using Dry Powder Inhalers
- 6.2. Other Protein Inhaler Technologies
- Competing Products in Clinical Trials
- 6.3. Pulmonary Delivery using Antibody Transcytosis Fusion Proteins
- 6.4. Nasal Delivery using Mucosal Absorption Enhancers, Part 1
- IntraVail Technology
- Pro Tek Excipients
- 6.5. Nasal Delivery using Mucosal Absorption Enhancers, Part 2
- 6.6. Nasal Delivery via Tight Junction Modulation
Chapter 7 EXPERT INTERVIEWS
- 7.1. Abe S. Abuchowski, PhD, CEO, Prolong Pharmaceuticals
- 7.2. Ajay K. Banga, PhD, Professor and Chair, Department of Pharmaceutical
Sciences, Mercer University
- 7.3. Eric Tomlinson, DSc, PhD, President and CEO, Altea Therapeutics
- 7.4. Manuel Vega, PhD, CEO Nautilus Biotech
APPENDIX: CHI ADVANCES REPORTS - PROTEIN DRUG DELIVERY SURVEY - DECEMBER 2006
COMPANY INDEX WITH WEB ADDRESSES
REFERENCES
|